This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Baxter's (BAX) New Premix Drug Now Available in the U.S.
by Zacks Equity Research
Baxter's (BAX) latest frozen premix formulation is expected to support patient safety, simplify medication preparation and boost operational efficiencies.
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock Now
by Zacks Equity Research
Investors continue to be optimistic about Intuitive Surgical (ISRG) owing to its strength in robotics.
HealthEquity (HQY) New Tie Up to Meet Clients' Healthcare Needs
by Zacks Equity Research
HealthEquity's (HQY) latest collaboration is expected to enhance digital transformation with Microsoft Azure and build better experiences for customers and employees.
3 Reasons to Add Avanos (AVNS) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.
Philips (PHG) Inks 7-Year Partnership With Northwell Health
by Zacks Equity Research
Philips (PHG) announces that it has entered into a seven-year agreement with Northwell Health, one of the largest healthcare providers in the state of New York.
Masimo's (MASI) New FDA Clearance to Boost Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) receipt of the FDA's De Novo grant is expected to combat opioid overdoses by boosting patient monitoring.
Why Is Masimo (MASI) Up 0.2% Since Last Earnings Report?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Retain Cigna (CI) Stock Now
by Zacks Equity Research
Cigna (CI) remains well-poised for growth on the back of continually growing premiums within its Cigna Healthcare unit. Solid cash-generating abilities also enable it to deploy capital.
Masimo (MASI) Unveils Freedom Smartwatch With Privacy Switch
by Zacks Equity Research
Masimo's (MASI) newest wearable product seamlessly integrates continuous health tracking technology and breakthrough features.
Three Reasons to Add Masimo (MASI) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
HealthEquity (HQY) Beats on Q4 Earnings, Margins Rise
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, alongside recording robust performances in all its segments, in the fourth quarter of fiscal 2023.
Masimo (MASI) Moves to Strong Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Masimo (MASI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Masimo (MASI) PVi Achieves Acceptable Fluid Response in Study
by Zacks Equity Research
Masimo (MASI) PVi helps clinicians reliably predict fluid responsiveness in young neurosurgical patients.
Masimo (MASI) Q4 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Masimo's (MASI) robust product shipments and continued strength in its healthcare business drive its Q4 sales.
Masimo (MASI) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 12.82% and 2.67%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Masimo (MASI) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
Analysts Estimate Masimo (MASI) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Masimo's (MASI) Patient Monitoring Devices Favored by New Study
by Zacks Equity Research
Masimo's (MASI) patient monitoring devices continue to aid researchers in their assessment of different ventilatory strategies for brain oxygenation during thoracoscopic surgery.
Masimo (MASI) Expands Partnership with Philips for W1 Watch
by Zacks Equity Research
Masimo (MASI) and Royal Philips to create an open ecosystem of medical information using Masimo W1 watch and the latter???s patient monitoring ecosystem to improve home-care.
Here's Why You Should Retain Masimo (MASI) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
Masimo (MASI) Gets Favorable Ruling in Apple Watch Patent Suit
by Zacks Equity Research
A U.S. Administrative Law Judge ruled that Apple watches infringe one of Masimo's (MASI) pulse oximeter patents. An import ban may follow for Apple watches.
UnitedHealth's (UNH) UnitedHealthcare Unit to Aid Q4 Earnings?
by Zacks Equity Research
An increase in the number of people served in the commercial domestic business of UnitedHealth's (UNH) UnitedHealthcare segment is likely to boost fourth-quarter results.
UnitedHealth (UNH) to Post Q4 Earnings: What You Should Know
by Zacks Equity Research
UnitedHealth Group's (UNH) fourth-quarter results are likely to reflect growing premiums, products and higher expenses.
Masimo's (MASI) SpHb During Elective CS Favored by New Study
by Zacks Equity Research
Masimo's (MASI) SpHb is likely to indicate clinically acceptable accuracy of Hb measurement even at low Hb levels in patients undergoing CS with antepartum hemorrhage.
3 Beaten-Down MedTech Stocks Poised for a Turnaround in 2023
by Debanjana Dey
Here are some dirt-cheap MedTech value stocks - DYNT, INGN, AVNS - which are expected to provide long-term gains.